T1	Participants 443 505	large cohort of patients presenting across the spectrum of ACS
T2	Participants 537 657	(n = 3,761) and at four-months (n = 3,369) in patients randomized to atorvastatin 80 mg or pravastatin 40 mg after ACS i
